Skip to main content

Table 1 Trials registered to NCT for repurposed drugs, of which ongoing and suspended or withdrawn. Percentages are of all registered trials

From: Missing clinical trial data: the evidence gap in primary data for potential COVID-19 drugs

Generic name Total registered Ongoing Suspended/withdrawn Completed
Pirfenidone 86 30 (34.9%) 2 (2.3%) 54 (62.8%)
Hydroxychloroquine sulfate 233 74 (31.8%) 5 (2.1%) 154 (66.1%)
Azithromycin 457 98 (21.4%) 16 (3.5%) 343 (75.1%)
Favipiravir 12 3 (25.0%) 0 (0.0%) 9 (75.0%)
Oseltamivir 127 18 (14.2%) 8 (6.3%) 101 (79.5%)
Sarilumab 37 19 (51.4%) 0 (0.0%) 18 (48.6%)
Tocilizumab (atlizumab) 360 84 (23.3%) 9 (2.5%) 267 (74.2%)
Remdesivir 12 11 (91.7%) 0 (0.0%) 1 (8.3)
Leflunomide 25 4 (16.0%) 1 (4.0%) 20 (80.0%)
Interferon-alpha 1161 71 (6.1%) 41 (3.5%) 1049 (90.4%)
Lopinavir/ritonavir 1015 66 (6.5%) 22 (2.2%) 927 (91.3%)
Darunavir/ritonavir 246 26 (10.6%) 4 (1.6%) 216 (87.8%)
Baloxavir marboxil 9 4 (44.4%) 0 (0.0%) 5 (55.6%)
Umifenovir 10 8 (80.0%) 0 (0.0%) 2 (20.0%)
Interferon-beta 343 43 (12.5%) 15 (4.4%) 285 (83.1%)
Sofosbuvir 261 75 (28.7%) 10 (3.8%) 176 (67.4%)
Nitazoxanide 57 8 (14.0%) 1 (1.8%) 48 (84.2%)
APN01 (ACE2 analogue) 1 0 (0.0%) 0 (0.0%) 1 (100.0%)
Ivermectin 101 19 (18.8%) 4 (4.0%) 78 (77.2%)
Totals 4553 661 (14.5%) 138 (3.0%) 3754 (82.5%)